Several other research analysts have also recently issued reports on BLFS. Northland Securities upped their price objective on BioLife Solutions from $18.00 to $22.00 and gave the stock an outperform rating in a research report on Wednesday, September 4th. HC Wainwright initiated coverage on BioLife Solutions in a research report on Monday, July 22nd. They set a buy rating and a $23.00 price objective for the company. ValuEngine cut BioLife Solutions from a hold rating to a sell rating in a research report on Thursday. Zacks Investment Research cut BioLife Solutions from a buy rating to a hold rating in a research report on Wednesday, October 30th. Finally, Maxim Group set a $26.00 price objective on BioLife Solutions and gave the stock a buy rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. BioLife Solutions has a consensus rating of Buy and a consensus target price of $18.40.
Shares of NASDAQ:BLFS traded down $0.48 on Thursday, hitting $14.77. 180,000 shares of the company’s stock were exchanged, compared to its average volume of 175,961. The firm’s 50-day moving average is $16.36 and its 200 day moving average is $17.71. The company has a market capitalization of $301.67 million, a PE ratio of 105.50 and a beta of 1.35. BioLife Solutions has a 1-year low of $9.15 and a 1-year high of $22.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.71 and a current ratio of 6.49.
In other news, Director Andrew G. Hinson sold 6,000 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $20.07, for a total value of $120,420.00. Following the completion of the sale, the director now directly owns 15,747 shares of the company’s stock, valued at approximately $316,042.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP James Mathers sold 2,500 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.06, for a total value of $50,150.00. Following the completion of the sale, the vice president now directly owns 19,884 shares of the company’s stock, valued at $398,873.04. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 195,794 shares of company stock valued at $3,629,637. Insiders own 27.00% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $30,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $170,000. Morgan Stanley lifted its holdings in shares of BioLife Solutions by 17.5% in the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after purchasing an additional 1,713 shares during the last quarter. Menta Capital LLC purchased a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $202,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $283,000. 46.22% of the stock is owned by institutional investors and hedge funds.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Featured Story: 52-Week High/Low
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.